Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
The Readout

Esperion’s tough sell & Achaogen’s split verdict

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan May 3, 2018

Reprints
The READOUT
Alex Hogan/STAT

The Readout for May 03, 2018

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Arthur Ashe and AIDS: Did the public have the…
Arthur Ashe and AIDS: Did the public have the right to know his diagnosis?
Human reproductive cloning: The curious incident of the dog…
Human reproductive cloning: The curious incident of the dog in the night-time
Drug used to halt puberty in children may cause…
Drug used to halt puberty in children may cause lasting health problems
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories